Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2004-07-02
2010-10-12
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S002600, C424S184100
Reexamination Certificate
active
07812116
ABSTRACT:
The invention provides relatively short immunogenic peptides derived from CD19 and CD20 antigens, and biologically active variants thereof, which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can be included in pharmaceutical compositions, such as cancer vaccines, and used for the treatment of cancer.
REFERENCES:
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4777127 (1988-10-01), Suni et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5939526 (1999-08-01), Gaugler et al.
patent: 6271019 (2001-08-01), Van Baren et al.
patent: 6291430 (2001-09-01), Chaux et al.
patent: 6306640 (2001-10-01), Nicolette
patent: 6344203 (2002-02-01), Sandrin et al.
patent: 6440386 (2002-08-01), Leung
patent: 0345242 (1989-12-01), None
patent: 2200651 (1988-08-01), None
patent: WO 89/01973 (1989-03-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 91/02805 (1991-03-01), None
Hooijberg et al., J Immunother Emphais Tumor Immunol, vol. suppl 2, s43-5, 1996.
Nestle et al., Amer J of Path, vol. 150, p. 641-651, 1997.
Tomb et al., Nature, vol. 388, p. 539-543, 1997 and NCBI accession No. 7464360.
Harper et al., J of Immunology, vol. 147, p. 1037-1044 and NCBI accession No. 2134978.
Zhou et al., Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes:Immunogenetics35(2), pp. 102-111, 1992 (abstract).
Stamenkovic at al., “CD19, the earliest differentiation antigen of the B cell lineage, bears three extra cellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail”J Exp Med168, pp. 1205-1210, 1988 (abstract).
Tedder et al., “The CD19/CD21 signal transduction complex of B lymphocytes”Immunol Today15, p. 437, 1994 (abstract).
Otero et al., “CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals”J Immunol170(1), pp. 73-83, 2003 (abstract).
Zhou et al., “Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain”J Immunol147(4), pp. 1424-1432, 1991 (abstract).
Liu et al., “A BsmFI PCR/RFLP in the canine CD19 gene”Anim Genet29(1), pp. 64-65, 1998.
Sun et al., “Cloning, sequenginc and expression of swine CD19” http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=protein&list—uids=18496846&dopt=GenPept.
Tedder et al., “Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily”J Immunol143, pp. 712-717, 1989 (abstract).
Bejcek et al., “Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against ehe CD19 antigen”Cancer Res55 (11), pp. 2346-2351, 1995 (abstract).
Tulpule et al., “Anti-B4 (CD 19) monoclonal antibody, conjugated with ricin (B4-blocked ricin: B4bR) in refractory AIDS-lymphoma”Proc Ann Meet Am Soc Clin Oncol13, p. A10, 1994 (abstract).
Dörken et al., “Leucocyte Typing IV: White Cell Differentiation Antigens,” In: Knapp W., Dörken B, Gilks WR et al., eds. Leucocyte Typing IV:White Cell Differentiation Antigens. Oxford: Oxford University Press, pp. 46-48, 1989.
Loken et al., “Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte developments”Blood70, pp. 1316-1324, 1987 (abstract).
Hultin et al., “CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes”Cytometry14, pp. 196-204, 1993 (abstract).
Algino et al., “CD20 (pan-B cell antigen) expression on bone marrow-derived cells”Am J Clin Pathol106(1), pp. 78-81, Jul. 1996 (abstract).
Scheuermann et al.,“CD 19 antigen in leukemia and lymphoma diagnosis and immunotherapy”Leuk Lymphoma18(5-6), pp. 385-397, 1995 (abstract).
Stamenkovic et al., “Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein”J Exp Med167 (6), pp. 1975-1980, 1988 (abstract).
Tedder et al., “Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes”Proc Natl Acad Sci USA85 (1), pp. 208-212, 1988 (abstract).
Tedder et al., Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1)J Immunol142 (7), pp. 2560-2568, 1989 (abstract).
Einfeld et al.,“Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains”EMBO J7 (3), pp. 711-717, 1988 (abstract).
Strausberg et al., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”Proc Natl Acad Sci USA99 (26), pp. 16899-16903, 2002 (abstract).
Macardle et al.,“CD20”J Bio. Regul Homeost Agents16 (2), pp. 136-138, 2002, (mus musculus).
Van den Eynde & Brichard, :New tumor antigens recognized by T cellsCurr Opin Immunol7, pp. 674-681, 1995 (abstract).
Coulie et al., “Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination?”Stem Cells13, pp. 393-403, 1995 (abstract).
Roberts et al., “Vaccination with CD20 peptides induces a biologically active, specific immune response in mice”Blood99 (10), pp. 3748-3755, 2002 (abstract).
Molecular Cloning:A Laboratory Manual, J. Sambrook et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
Current Protocols in Molecular Biology, F. M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York.
Hopp et al., “A short polypeptide marker sequence useful for recombinant protein and purification”BioTechnology6, p. 1204, 1988.
Nachman et al., “Pseudodipeptie analogs of the pyrokinin/PBAN (FXPRLa) insect neuropeptide family containing carrbocyclic Pro-mimetic conformational components”Regul Pept57, pp. 359-370, 1995 (abstract).
Gene Expression Technology, Goeddel ed., Academic Press, Inc., 1991.
Vectors:Essential Data Series, Gacesa and Ramji, eds, John Wiley & Sons, NY, 1994.
Miller A D et al., “Improved retroviral vectors for gene transfer and expression”BioTechniques7, pp. 980-990, 1989 (abstract).
Correll et al., “Production of human glucocerebrosidase in mice after retrovira gene transfer into multipotential hematopoietic progenitor cells”Proc Natl Acad Sci USA86, p. 8912, 1989 (abstract).
Bordignon, “Retroviral vector-mediated high-efficiency expression of adenosine deminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells”Proc Natl Acad Sci USA86, pp. 6748-6752, 1989.
Culver K, “Lymphocytes as cellular vehicles for gene therapy in mouse and man”Proc Natl Acad Sci USA88, p. 3155, 1991.
Rill D R, “An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer”Blood79 (10), pp. 2694-2700, 1991 (abstract).
Steplewski et al., “Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants”Proc Natl Acad Sci82, p. 8653, 1985 (abstract).
Spira et al., “The identification of monoclonal class switch variants by sib selection and an ELISA assay”J Immunol Methods74, p. 307, 1984 (abstract).
Herlyn et al., “Anti-idiotypic antibodies bear the internal image of a human tumor antigen”Science232, p. 100, 1986 (abstract).
Lodge et al., “Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial”Cancer Res60, p. 829, 2000.
Lau et al., “Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastat
Foley & Lardner LLP
Helms Larry R.
Rush University Medical Center
Yao Lei
LandOfFree
Immunogenic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224637